ABT-263: A Potent and Orally Bioavailable Bcl-2 Family InhibitorChristin Tse, Steven W. Elmore, Eric F. Johnson et al.|Cancer Research|2008Cited by 2k
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapyJoel D. Leverson, Andrew J. Souers, Darren C. Phillips et al.|Science Translational Medicine|2015Cited by 541
SnoN suppresses TGF-β-induced epithelial-mesenchymal transition and invasion of bladder cancer in a TIF1γ-dependent mannerXinbao Yin, Jun Chen|Oncology Reports|2016Cited by 15